lunes, 2 de marzo de 2026
Psoriasis: Addressing Weight Loss in Patients | How Biologics Continue to Transform Dermatologic Care +++++ +
Weight Loss and Psoriasis: How to Talk With Patients and Take a Comprehensive Approach
Christine Kilgore
https://www.medscape.com/viewarticle/weight-loss-and-psoriasis-how-talk-patients-and-take-2026a100023y?ecd=mkm_ret_260302_mscpmrk-OUS_InFocus_etid8138823&uac=148436CN&impID=8138823
January 22, 2026
Bimekizumab Eases Plaque Psoriasis Symptoms Up to 3 Years
Edited by Deepa Varma
https://www.medscape.com/viewarticle/bimekizumab-eases-plaque-psoriasis-symptoms-3-years-2026a100052j?ecd=mkm_ret_260302_mscpmrk-OUS_InFocus_etid8138823&uac=148436CN&impID=8138823
February 18, 2026
Biologics Continue to Transform Dermatology, With Safer and More Effective Care
Damian McNamara, MA
https://www.medscape.com/viewarticle/biologics-continue-transform-dermatology-safer-and-more-2026a10004du?ecd=mkm_ret_260302_mscpmrk-OUS_InFocus_etid8138823&uac=148436CN&impID=8138823
February 11, 2026
Pediatric Psoriasis Lacks Clear Guidance for Everyday Care
Caroline Guignot
https://www.medscape.com/viewarticle/pediatric-psoriasis-lacks-clear-guidance-everyday-care-2026a10001iq?ecd=mkm_ret_260302_mscpmrk-OUS_InFocus_etid8138823&uac=148436CN&impID=8138823
Medscape Europe
January 16, 2026
Biologic Plus GLP-1 Agonist Improves Quality of Life in Psoriatic Disease
Ted Bosworth
https://www.medscape.com/viewarticle/biologic-plus-glp-1-agonist-improves-quality-life-psoriatic-2026a10002s0?ecd=mkm_ret_260302_mscpmrk-OUS_InFocus_etid8138823&uac=148436CN&impID=8138823
January 28, 2026
Patient with plaque psoriasis asking about a study mentioned in online support group about high dose risankizumab. What is the latest? (Medscape AI)
https://www.medscape.com/ai-search?query=Patient%20with%20plaque%20psoriasis%20asking%20about%20a%20study%20mentioned%20in%20online%20support%20group%20about%20high%20dose%20risankizumab.%20What%20is%20the%20latest%3F&&ecd=mkm_ret_260302_mscpmrk-OUS_InFocus_etid8138823&uac=148436CN&impID=8138823
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario